UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
HemaSphere, ISSN 2572-9241, 06/2019, Volume 3, p. 112
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 20, pp. 2766 - 2772
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Doxorubicin - therapeutic use | Recurrence | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Testicular Neoplasms - pathology | Central Nervous System Neoplasms - secondary | Testicular Neoplasms - radiotherapy | Central Nervous System Neoplasms - prevention & control | Drug-Related Side Effects and Adverse Reactions | Adult | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Lymphoma, Large B-Cell, Diffuse - pathology | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - radiotherapy | Methotrexate - adverse effects | Testicular Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Methotrexate - administration & dosage | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 09/2018, Volume 19, Issue 9, pp. 1144 - 1146
Journal Article
The lancet oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 162 - 163
Journal Article
British journal of haematology, ISSN 0007-1048, 11/2020
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 730 - 737
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Thalidomide - adverse effects | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Thalidomide - administration & dosage | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - mortality | Thalidomide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Vincristine - administration & dosage | Vincristine - adverse effects | Female | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Doxorubicin - administration & dosage | Aged patients | Anthracyclines | Product development | Corticosteroids | Angiogenesis inhibitors | Public health | Analysis | Index Medicus
Journal Article
The Lancet. Haematology, ISSN 2352-3026, 05/2019, Volume 6, Issue 5, pp. e232 - e233
Journal Article
The lancet oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. e558 - e558
Journal Article
Future oncology (London, England), ISSN 1479-6694, 04/2017, Volume 13, Issue 10, pp. 859 - 862
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 12, pp. 1376 - 1385
Life Sciences & Biomedicine | Oncology | Science & Technology | Hodgkin Disease - diagnostic imaging | Predictive Value of Tests | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Positron-Emission Tomography | Patient Selection | Young Adult | Time Factors | Hodgkin Disease - mortality | Adult | Female | Stem Cell Transplantation - mortality | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Italy | Aged | Drug Substitution | Neoplasm Staging | Stem Cell Transplantation - adverse effects | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Hodgkin's disease | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 229 - 240
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Double-Blind Method | Humans | Middle Aged | Immunologic Factors - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Immunoconjugates - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Large-Cell, Anaplastic - drug therapy | Intention to Treat Analysis | Vincristine - administration & dosage | Adult | Female | Aged | Immunologic Factors - adverse effects | Brentuximab Vedotin | Doxorubicin - administration & dosage | Immunoconjugates - adverse effects | Leukemia | Clinical trials | Lymphocytes T | Peripheral neuropathy | Cancer therapies | Doxorubicin | Evidence-based medicine | Regulatory approval | Randomization | CD30 antigen | Safety management | Genetics | Safety | Active control | Neutropenia | Cell survival | Prednisone | Patients | Survival | Vincristine | Lymphoma | Cyclophosphamide | Chemotherapy | Medical prognosis | Adults | Interferon | Anaplastic large-cell lymphoma | T-cell lymphoma | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 09/2009, Volume 27, Issue 27, pp. 4555 - 4562
Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Predictive Value of Tests | Lymphoma, Follicular - therapy | Prognosis | Risk Assessment | Humans | Middle Aged | Lymphoma, Follicular - diagnosis | Disease Progression | Young Adult | Disease-Free Survival | Aged, 80 and over | Adult | Aged | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 5, pp. 565 - 572
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Chlorambucil - administration & dosage | Drug Administration Schedule | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Rituximab | Male | Treatment Outcome | Remission Induction | Lymphoma, B-Cell, Marginal Zone - mortality | Disease-Free Survival | Analysis of Variance | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, B-Cell, Marginal Zone - drug therapy | Adult | Female | Aged | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 08/2007, Volume 25, Issue 24, pp. 3746 - 3752
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Hodgkin Disease - diagnostic imaging | Prognosis | Humans | Middle Aged | Male | Survival Rate | Disease-Free Survival | Adolescent | Radionuclide Imaging | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Fluorodeoxyglucose F18 | Aged | Radiopharmaceuticals | Index Medicus
Journal Article